A detailed history of Prism Advisors, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Prism Advisors, Inc. holds 251 shares of LLY stock, worth $192,707. This represents 0.06% of its overall portfolio holdings.

Number of Shares
251
Previous 251 -0.0%
Holding current value
$192,707
Previous $227,000 2.2%
% of portfolio
0.06%
Previous 0.07%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 10, 2024

BUY
$724.87 - $909.04 $181,942 - $228,169
251 New
251 $227,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $730B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Prism Advisors, Inc. Portfolio

Follow Prism Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prism Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Prism Advisors, Inc. with notifications on news.